Viewing Study NCT06008093

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 1:20 AM
Ignite Modification Date: 2026-02-06 @ 4:48 AM
Study NCT ID: NCT06008093
Status: RECRUITING
Last Update Posted: 2025-10-27
First Post: 2023-08-17
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
Sponsor: AstraZeneca
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Carcinoma, Non-Small-Cell Lung View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Mutation View
None Metastatic Non-Small Cell Lung Cancer View
None Kelch-Like ECH-Associated Protein 1 (KEAP1) View
None Kirsten rat sarcoma virus (KRAS) View
None Programmed death-ligand 1 (PD-L1) View
None Serine/threonine kinase 11 (STK11) View